Patent cliffs & loss of exclusivity
Travere Therapeutics is a Nasdaq-listed (TVTX) biopharmaceutical company headquartered in San Diego, California, that develops and commercialises therapies for people with rare kidney and metabolic diseases. The company traces its roots to Retrophin, founded in 2011, which renamed itself Travere Therapeutics in November 2020. Its marketed products are FILSPARI (sparsentan), approved for IgA nephropathy, and THIOLA and THIOLA EC (tiopronin) for cystinuria; it sold its bile acid products Cholbam and Chenodal to Mirum Pharmaceuticals in 2023. Eric Dube is president and chief executive officer, and the company reported 497 full-time employees in its annual report for 2025.
| AngelList URL | https://angel.co/retrophin |
|---|---|
| Legal Name | Travere Therapeutics, Inc. |
| Company Operating Status | Active |
| Contact Page URL | https://travere.com/contact-us/ |
| Crunchbase URL | https://www.crunchbase.com/organization/retrophin |
| Email format | {first}.{last} |
| Facebook URL | https://www.facebook.com/TravereRare/ |
| Full Address | 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130, USA |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.